Erhardt JA - Search Results

1

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.

King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A, Kane-Carson LS, Sinnamon RH, Qi H, Rheault TR, Uehling DE, Laquerre SG. King AJ, et al. Among authors: erhardt ja. PLoS One. 2013 Jul 3;8(7):e67583. doi: 10.1371/journal.pone.0067583. Print 2013. PLoS One. 2013. PMID: 23844038 Free PMC article.

2

Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.

Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Erhardt JA, et al. Exp Hematol. 2009 Sep;37(9):1030-7. doi: 10.1016/j.exphem.2009.06.011. Epub 2009 Jul 24. Exp Hematol. 2009. PMID: 19631713 Free article.

3

SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.

Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ, Erhardt JA, Nelson AH, Ohlstein EH, Hunter AJ, Ward K, Smith BR, Adams JL, Parsons AA. Barone FC, et al. Among authors: erhardt ja. J Pharmacol Exp Ther. 2001 Feb;296(2):312-21. J Pharmacol Exp Ther. 2001. PMID: 11160612

4

Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists.

Thalji RK, Aiyar N, Davenport EA, Erhardt JA, Kallal LA, Morrow DM, Senadhi S, Burns-Kurtis CL, Marino JP Jr. Thalji RK, et al. Among authors: erhardt ja. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4104-7. doi: 10.1016/j.bmcl.2010.05.072. Epub 2010 Jun 9. Bioorg Med Chem Lett. 2010. PMID: 20542694

5

The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury.

Legos JJ, McLaughlin B, Skaper SD, Strijbos PJ, Parsons AA, Aizenman E, Herin GA, Barone FC, Erhardt JA. Legos JJ, et al. Among authors: erhardt ja. Eur J Pharmacol. 2002 Jun 28;447(1):37-42. doi: 10.1016/s0014-2999(02)01890-3. Eur J Pharmacol. 2002. PMID: 12106800

6

Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation.

Mills JC, Stone NL, Erhardt J, Pittman RN. Mills JC, et al. J Cell Biol. 1998 Feb 9;140(3):627-36. doi: 10.1083/jcb.140.3.627. J Cell Biol. 1998. PMID: 9456322 Free PMC article.

7

Potentiation of platelet activation through the stimulation of P2X1 receptors.

Erhardt JA, Pillarisetti K, Toomey JR. Erhardt JA, et al. J Thromb Haemost. 2003 Dec;1(12):2626-35. doi: 10.1046/j.1538-7836.2003.00453.x. J Thromb Haemost. 2003. PMID: 14675100 Free article.

8

P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation.

Erhardt JA, Toomey JR, Douglas SA, Johns DG. Erhardt JA, et al. J Thromb Haemost. 2006 Apr;4(4):882-90. doi: 10.1111/j.1538-7836.2006.01849.x. J Thromb Haemost. 2006. PMID: 16634759 Free article.

9

A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis.

Toomey JR, Abboud MA, Valocik RE, Koster PF, Burns-Kurtis CL, Pillarisetti K, Danoff TM, Erhardt JA. Toomey JR, et al. Among authors: erhardt ja. J Thromb Haemost. 2006 Sep;4(9):1989-96. doi: 10.1111/j.1538-7836.2006.02064.x. J Thromb Haemost. 2006. PMID: 16961606 Free article.

10

Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban.

Erhardt JA, Ohlstein EH, Toomey JR, Gabriel MA, Willette RN, Yue TL, Barone FC, Parsons AA. Erhardt JA, et al. Thromb Res. 2001 Jul 15;103(2):143-8. doi: 10.1016/s0049-3848(01)00287-0. Thromb Res. 2001. PMID: 11457472 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters